Intra-artery infusion of recombinant human erythropoietin reduces blood-brain barrier disruption in rats following cerebral ischemia and reperfusion

International Journal of Neuroscience

Volumn 125, Issue 9, 2015, Pages 693-702

  Wang, Rongliang ^a,b   Wu, Xiaoning ^c   Liang, Jia ^a,b   Qi, Zhifeng ^a,b   Liu, Xiangrong ^a,b   Min, Lianqiu ^c   Ji, Xunming ^a   Luo, Yumin ^a,b   Zhao, Haiping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

blood brain barrier; brain ischemia; edema; erythropoietin; MMPs

Indexed keywords

CLAUDIN 5; EVANS BLUE; GELATINASE A; GELATINASE B; OCCLUDIN; RECOMBINANT ERYTHROPOIETIN; TIGHT JUNCTION PROTEIN; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRAVASATION; FEMALE; IMMUNOFLUORESCENCE; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; CEREBRAL ARTERY DISEASE; CEREBRAL INFARCTION; COMPLICATION; DRUG EFFECTS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; CEREBRAL INFARCTION; ERYTHROPOIETIN; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRA-ARTERIAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REPERFUSION INJURY;

EID: 84939238584     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.966354     Document Type: Article

References (21)

1. Marler JR, Goldstein LB. Stroke-tPA and the clinic. Science 2003; 301: 1677.
2. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here. A cumulative meta-analysis. Stroke 2003; 34: 1437-42.
3. Subirós N, Del Barco DG, Coro-Antich RM. Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 2012; 5: 161-73.
4. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
5. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-75.
6. Iwai M, Cao G, Yin W, et al. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007; 38: 2795-2803.
7. Nguyen AQ, Cherry BH, Scott GF, et al. Erythropoietin: powerful protection of ischemic and post-ischemic brain. Exp Biol Med 2014. (. Epub ahead of print).
8. Dang S, Liu X, Fu P, et al. Neuroprotection by local intra-arterial infusion of erythropoietin after focal cerebral ischemia in rats. Neurol Res 2011; 33: 520-28.
9. Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709.
10. Liu K, Sun T, Wang P, et al. Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats. J Mol Neurosci 2013; 49: 369-79.
11. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
12. Belayev L, Alonso OF, Busto R, et al. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996; 27: 1616-23.
13. Biegel D, Spence DD, Pachter JS. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res 1995; 692: 183-89.
14. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007; 38 (2 Suppl): 748-52.
15. Woitzik J, Schilling L. A new method for superselective middle cerebral artery infusion in the rat. J Neurosurg 2007; 106: 872-78.
16. Spatz, M. Past and recent BBB studies with particular emphasis on changes in ischemic brain edema. Acta Neurochir Suppl 2010; 106: 21-27.
17. Lakhan SE, Kirchgessner A, Tepper D, et al. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol 2013; 4: 32.
18. Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709.
19. Rogers DC, Campbell CA, Stretton JL, et al. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 1997; 28: 2060-65.
20. Chan CY, Chen YS, Lee HH, et al. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci 2007; 81: 717-23.
21. Kadri Z, Maouche-Chretien L, Rooke HM, et al. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol 2005; 25: 7412-22.